Immunotherapy in EGFR-mutant non-small cell lung cancer

Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR).For driver mutations, the use of EGFR tyrosine kinase inhibitors (TKIs) is the standard treatment, but acquired resistance is inevitable. There is currently no standard treatment for first-line TKI-resistant NSCLC patients. In recent years, although immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced NSCLC without driver gene mutations, the clinical efficacy of these agents in patients with advanced NSCLC harboring EGFR mutations remains limited. Whether ICIs are suitable for patients with EGFR-mutated advanced NSCLC still warrants further investigation.This review summarizes several clinically utilized ICIs, presents clinical evidence regarding the efficacy of immunotherapy in patients with EGFR-mutated advanced NSCLC, and identifies EGFR-mutated subpopulations that may benefit from ICI treatment. On this basis, we explored more effective therapeutic strategies to extend the benefits of immunotherapy to a larger cohort of patients with EGFR-mutated NSCLC.